Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$36.86 - $44.5 $246,962 - $298,150
-6,700 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$40.32 - $50.97 $379,008 - $479,118
-9,400 Reduced 58.39%
6,700 $280,000
Q4 2020

Feb 12, 2021

BUY
$41.72 - $51.34 $671,692 - $826,574
16,100 New
16,100 $750,000
Q3 2020

Nov 12, 2020

SELL
$37.02 - $51.28 $511,357 - $708,330
-13,813 Closed
0 $0
Q2 2020

Aug 12, 2020

BUY
$43.24 - $55.02 $4,324 - $5,502
100 Added 0.73%
13,813 $663,000
Q1 2020

May 15, 2020

SELL
$34.37 - $60.07 $461,039 - $805,778
-13,414 Reduced 49.45%
13,713 $631,000
Q4 2019

Feb 13, 2020

BUY
$54.32 - $64.31 $1.47 Million - $1.74 Million
27,127 New
27,127 $1.63 Million
Q3 2018

Nov 14, 2018

SELL
$66.65 - $83.86 $268,599 - $337,955
-4,030 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$51.25 - $76.62 $221,297 - $330,845
-4,318 Reduced 51.72%
4,030 $305,000
Q1 2018

May 14, 2018

SELL
$52.16 - $66.86 $8.75 Million - $11.2 Million
-167,838 Reduced 95.26%
8,348 $440,000
Q4 2017

Feb 09, 2018

SELL
$49.6 - $60.87 $1.97 Million - $2.42 Million
-39,809 Reduced 18.43%
176,186 $9.41 Million
Q3 2017

Nov 14, 2017

BUY
$46.62 - $60.36 $10.1 Million - $13 Million
215,995
215,995 $12.9 Million

Others Institutions Holding EGRX

About EAGLE PHARMACEUTICALS, INC.


  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $15.1M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Arrowstreet Capital, Limited Partnership Portfolio

Follow Arrowstreet Capital, Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.